Hvad er oversættelsen af " IN VITRO- UNDERSØGELSER " på engelsk?

• in vitro studies
• in vitro investigations

Eksempler på brug af In vitro- undersøgelser på Dansk og deres oversættelser til Engelsk

In vitro- undersøgelser har vist, at montelukast er en potent hæmmer af CYP2C8.
In vitro studies have shown that montelukast is a potent inhibitor of CYP 2C8.

Nateglinid har vist lavt potentiale for proteindeplacering i in vitro- undersøgelser.
Nateglinide has shown a low potential for protein displacement in in vitro studies.

In vitro- undersøgelser har ikke vist hæmning af nogen undertype af cytokrom P450.
In vitro studies have shown no inhibition of any subtype of cytochrome P450.

Specificiteten af eculizumab for C5 i humant serum blev bestemt i to in vitro- undersøgelser.
The specificity of eculizumab for C5 in human serum was evaluated in two in vitro studies.

In vitro- undersøgelser har ikke vist holdepunkter for, at pioglitazon hæmmer nogen undertype af cytokrom P450.
In vitro studies have shown no evidence that pioglitazone inhibits any subtype of cytochrome P450.

Det er usandsynligt at atosiban skulle være involveret i cytokrom P450 medierede lægemiddel- lægemiddelinteraktioner, eftersom in vitro- undersøgelser har vist at atosiban ikke er substrat for cytokrom P450 systemet, og ikke hæmmer lægemiddel metaboliserende cytokrom P450 enzymer.
It is unlikely that atosiban is involved in cytochrome P450 mediated drug-drug interactions as in vitro investigations have shown that atosiban is not a substrate for the cytochrome P450 system, and does not inhibit the drug metabolising cytochrome P450 enzymes.

In vitro- undersøgelser har vist, at rosiglitazon primært metaboliseres af CYP2C8 og i mindre omfang af CYP2C9.
In vitro studies demonstrate that rosiglitazone is predominantly metabolised by CYP2C8, with a minor contribution by CYP2C9.

Baseret på in vitro- undersøgelser forventes etoricoxib ikke at hæmme cytokrom P450(CYP) 1A2, 2C9, 2C19, 2D6, 2E1 eller 3A4.
Based on in vitro studies, etoricoxib is not expected to inhibit cytochromes P450(CYP) 1A2, 2C9, 2C19, 2D6, 2E1 or 3A4.

In vitro- undersøgelser har vist fortrængning af nimesulfide fra bindingssteder af tolbutamide, salicylsyre og valproic acid.
In vitro studies have shown displacement of nimesulide from binding sites by tolbutamide, salicylic acid and valproic acid.

I in vitro- undersøgelser hæmmede laropiprant ikke CYP1A2, CYP2B6, CYP2C19, CYP2D6 eller CYP2E1- medierede reaktioner.
In in vitro studies, laropiprant did not inhibit CYP1A2, CYP2B6, CYP2C19, CYP2D6, or CYP2E1-mediated reactions.

Kliniske og in vitro- undersøgelser understøtter den konklusion, at laropiprant er en mild til moderat hæmmer af UGT2B4/ UGT2B7.
Clinical and in vitro studies support the conclusion that laropiprant is a mild to moderate inhibitor of UGT2B4/ UGT2B7.

In vitro- undersøgelser har vist, at rosiglitazon primært metaboliseres af CYP2C8, med CYP2C9 som en mindre metaboliseringsvej.
In vitro studies demonstrate that rosiglitazone is predominantly metabolised by CYP2C8, with CYP2C9 as only a minor pathway.

In vitro- undersøgelser viser, at irbesartan primært oxideres af cytokrom P450 enzymet CYP2C9. Isoenzym CYP3A4 har kun ubetydelig effekt.
In vitro studies indicate that irbesartan is primarily oxidised by the cytochrome P450 enzyme CYP2C9; isoenzyme CYP3A4 has negligible effect.

In vitro- undersøgelser med humane levermikrosomer indikerer, at cytokrom P450 3A4, 2A6 og 2C9 er involverede i metaboliseringen af montelukast.
In vitro studies using human liver microsomes indicate that cytochrome P450 3A4, 2A6 and 2C9 are involved in the metabolism of montelukast.

In vitro- undersøgelser har vist, at potentialet for interaktion med andre lægemidler og proteinbindende interaktioner er meget lavt se afsnit 5. 2.
In vitro studies have demonstrated a very low potential for interaction with other medicinal products and protein binding interactions see section 5.2.

In vitro- undersøgelser har vist, at rivaroxaban er et substrat af transportproteinerne P- gp(P- glycoprotein) og Bcrp brystcancer- resistensprotein.
Based on in vitro investigations rivaroxaban is a substrate of the transporter proteins P-gp(P-glycoprotein) and Bcrp breast cancer resistance protein.

In vitro- undersøgelser tyder på, at zidovudin- resistente virusisolater kan blive zidovudin- følsomme, hvis de samtidig udvikler resistens over for lamivudin.
In vitro studies indicate that zidovudine-resistant virus isolates can become zidovudine sensitive when they simultaneously acquire resistance to lamivudine.

In vitro- undersøgelser for plasmaproteinbinding indikerer, at abacavir kun i begrænset til moderat omfang(~49%) bindes til humane plasmaproteiner ved terapeutiske koncentrationer.
Plasma protein binding studies in vitro indicate that abacavir binds only low to moderately(~ 49%) to human plasma proteins at therapeutic concentrations.

In vitro- undersøgelser Der blev foretaget en undersøgelse af den potentielle farmakokinetiske interaktion mellem clopidogrel og cerivastatin i mikrosomer fra human lever.
In vitro studies An investigation of the potential pharmacokinetic clopidogrel/ cerivastatin interaction was conducted in human liver microsomes.

In vitro- undersøgelser har vist, at ceftriaxon kan flytte bilirubin fra dets binding til serumalbumin, og disse patienter kan muligvis udvikle bilirubin- encephalopati.
In vitro studies have shown that ceftriaxone can displace bilirubin from its binding to serum albumin and bilirubin encephalopathy can possibly develop in these patients.

I in vitro- undersøgelser blev det fastslået, at daptomycin hverken hæmmer eller fremkalder klinisk signifikant aktivitet i humane CYP- isoformer lA2, 2A6, 2C9, 2C19, 2D6, 2E1, 3A4.
In vitro studies have determined that daptomycin does not inhibit or induce the activities of clinically significant human CYP isoforms 1A2, 2A6, 2C9, 2C19, 2D6, 2E1, 3A4.

I in vitro- undersøgelser af bl. a. binding til insulin- og IGF- 1- receptorsteder samt virkning på cellevækst opførte insulin aspart sig meget lig humant insulin.
In in vitro tests, including binding to insulin and IGF-1 receptor sites and effects on cell growth, insulin aspart behaved in a manner that closely resembled human insulin.

In vitro- undersøgelser indikerer, at CYP2D6, CYP2C9, CYP1A2 og CYP2C19 også kan katalysere den primære metaboliseringsvej, men deres kvantitative roller in vivo er ikke undersøgt.
In vitro studies indicate that CYP2D6, CYP2C9, CYP1A2 and CYP2C19 also can catalyse the main metabolic pathway, but their quantitative roles have not been studied in vivo.

In vitro- undersøgelser med humane levermikrosomer viste, at disse oxidative metabolitter primært blev dannet ved CYP1A1, CYP1A2, CYP2C8 eller CYP2C9, og febuxostat glukuronid blev hovedsagelig dannet ved UGT 1A1, 1A8 og 1A9.
In vitro studies with human liver microsomes showed that those oxidative metabolites were formed primarily by CYP1A1, CYP1A2, CYP2C8 or CYP2C9 and febuxostat glucuronide was formed mainly by UGT 1A1, 1A8, and 1A9.

Humane undersøgelser og in vitro- undersøgelser med anvendelse af humane levermikrosomer har vist, at efavirenz hovedsageligt metaboliseres til hydroxylerede metabolitter af cytokrom P450- systemet med efterfølgende glucuronidering af disse hydroxylerede metabolitter.
Studies in humans and in vitro studies using human liver microsomes have demonstrated that efavirenz is principally metabolised by the cytochrome P450 system to hydroxylated metabolites with subsequent glucuronidation of these hydroxylated metabolites.